I promise

"I promise, Suzy... Even if it takes the rest of my life." -Nancy G. Brinker, Founder of Susan G. Komen for the Cure

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Showing posts with label University of Toledo cancer research. Show all posts
Showing posts with label University of Toledo cancer research. Show all posts

Tuesday, January 26, 2021

The University of Toledo's Researcher, Dr. Amit Tiwari Awarded $1.4 Million to Advance Research in Promising New Chemotherapy for Triple Negative Breast Cancer

 

Melissa Paskvan 
and Dr. Tiwari
My TNBC researcher here in Toledo was just awarded another grant, this time from U.S. Department of Defense for $1.4 million to further his research in overcoming drug resistance in treatment therapy in Triple Negative Breast Cancer.  I am so proud to be a part of University of Toledo's Dr. Amit Tiwari's research team as their Patient Advocate Mentor for continued research on Triple Negative Breast Cancer.  Congratulations to D. Tiwari and his amazing team! I am glad that we found each other as partners in this fight against TNBC!

(Click link to story) 

UToledo Awarded $1.4 Million to Advance New Chemotherapy for Difficult-to-Treat Breast Cancer


"We are glad that you are part of our team.  Thank you for your wonderful spirit and passion to keep us moving forward." - Dr. Amit K. Tiwari


Sunday, March 8, 2020

University of Toledo Football 2019

Thank you Dr. Tiwari for the special invite to watch UT football and discuss cancer research with your collaborators in your department's suite for the evening.

with University of Toledo researchers and
Mary Westphal, CEO of Komen of NW, Ohio

University of Toledo,
Department of Pharmacology and
Experimental Therapeutics suite 

Our sweet suite!

University of Toledo Football

Mary Westphal, CEO of Komen NW Ohio
Dr. Amit Tiwari,
Triple Negative Breast Cancer researcher
and Melissa, Patient Advocate Mentor

Friday, March 6, 2020

University of Toledo Research Lab Visit February 20, 2020


Dr. Tiwari's Lab

Triple Negative Breast Cancer Research
at Dr. Amit Tiwari's lab

Storing Triple Negative Breast
Cancer cells for future studies

TNBC Researcher, Saloni marking
vials of Triple Negative Breast
Cancer cells

Counting Triple Negative Breast
Cancer cells under the microscope

Triple Negative Breast Cancer cells
on the rocking Shaker

Saloni removes Triple Negative 
Breast Cancer cells from 
the rocking shaker

Total Pageviews



"click image to link"